Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults

Abstract

IMPORTANCE More than 50% of older adults with late-life major depressive disorder fail to respond to initial treatment with first-line pharmacological therapy. OBJECTIVES To assess typical patterns of response to an open-label trial of extended-release venlafaxine hydrochloride (venlafaxine XR) for late-life depression and to evaluate which clinical factors are associated with the identified longitudinal response patterns. DESIGN, SETTING, AND PARTICIPANTS Group-based trajectory modeling was applied to data from a 12-week open-label pharmacological trial conducted in specialty care as part of the Incomplete Response in Late Life: Getting to Remission Study. Clinical prognostic factors, including domain-specific cognitive performance and individual depression symptoms, were examined in relation to response trajectories. Participants included 453 adults aged 60 years or older with current major depressive disorder. The study was conducted between August 2009 and August 2014. INTERVENTION Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks.MAIN OUTCOMES AND MEASURES Subgroups exhibiting similar response patterns were derived from repeated measures of overall depression severity obtained using the Montgomery-Asberg Depression Rating Scale.RESULTS Among the 453 study participants, 3 subgroups with differing baseline depression severity clearly responded to treatment: one group with the lowest baseline severity had a rapid response (n = 69 [15.23%]), and distinct responses were also apparent among groups starting at moderate (n = 108 [23.84%]) and higher (n = 25 [5.52%]) baseline symptom levels. Three subgroups had nonresponding trajectories: 2 with high baseline symptom levels (totaling 35.98%: high, nonresponse 1, n = 110 [24.28%]; high, nonresponse 2, n = 53 [11.70%]) and 1 with moderate baseline symptom levels (n = 88 [19.43%]). Several factors were independently associated with having a nonresponsive trajectory, including greater baseline depression severity, longer episode duration, less subjective sleep loss, more guilt, and more work/activity impairment (P < .05). Higher delayed memory (list recognition) performance was independently associated with having a rapid response (adjusted odds ratio = 2.22; 95% CI, 1.18-4.20). CONCLUSIONS AND RELEVANCEBased on the observed trajectory patterns, patients who have late-life depression with high baseline depression severity are unlikely to respond after 12 weeks of treatment with venlafaxine XR. However, high baseline depression severity alone may be neither a necessary nor sufficient predictor of treatment nonresponse.TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00892047

The relationship between estimated glomerular filtration rate trajectory and all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study

“…The censored normal model was used, with uncensored cases handled by specifying a minimum and maximum outside the range of the observed data values (33). The number of groups and degree of polynomial in each trajectory group was determined using the Bayesian Information Criterion, which measures improvement in model fit gained by adding additional groups or shape parameters incorporating a penalty for added complexity (13,14,34). Solutions that included small trajectory groups (<5% of the sample) were rejected.…”

Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder

“…First-line pharmacological treatments fail for over 50% of older adults with major depressive disorder (Joel et al, 2014, Mulsant et al, 2014, Smagula et al, 2015). Safe and efficacious adjunctive treatments for late-life major depressive disorder (LLD) are in high demand for the rapidly aging global population (Cauley, 2013).…”

“…We examined the roles of pain, physical function difficulties, and suicidality, which may mark etiopathological differences relevant to aripiprazole response. We also considered clinical characteristics previously related to first-line treatment outcomes (e.g., duration of the current depressive episode (Joel, Begley, 2014, Nelson et al, 2012, Smagula, Butters, 2015)). Variability in individual depressive symptom expression (i.e.…”

“…Variability in individual depressive symptom expression (i.e. items from the Hamilton Depression Rating Scale (Hamilton, 1960)) is associated with first-line treatment outcomes (Buhler et al, 2014, Smagula, Butters, 2015), but has yet to be examined as potential moderators of second-line treatments like aripiprazole. A primary side effect of aripiprazole includes akathisia, and we tested whether extrapyramidal symptoms (including akathisia) prior to treatment decreased the antidepressant efficacy of aripiprazole (e.g.…”

Acid Folic Supplementation in Major Depressive Disorder Treatment: A Double-Blind Randomized Clinical Trial

“…Although new therapeutic options have emerged in recent years, there are still many patients who do not respond to first-line antidepressants (6,7). Several strategies have been proposed for patients with refractory depression, including increasing the dosage of the antidepressant, switching the patient to new-generation medications, and adding another antidepressant medication to the patient's current treatment.…”